Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07782970

A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

The aim of this study is to assess the efficacy and safety of GSK5784283 administered as add-on maintenance therapy to participants with CRSwNP.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Nasal Polyps Nose Diseases Otorhinolaryngologic Diseases Paranasal Sinus Diseases Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Polyps Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age and older
  • Male or eligible female participants
  • Physician-diagnosed CRSwNP for greater than or equals to (>=) 12 months before screening.
  • Have had at least one of the following at Visit 1:
  • Any documented history of Nasal surgery for the removal of NP (or contraindications/intolerance to Nasal surgery)
  • Have used at least 3 consecutive days of Systemic corticosteroid (SCS) or 1 intramuscular depot injectable dose (or contraindications/intolerance to SCS) in the previous 12 months (but not in the past 3 months before screening) for the treatment of NP.
  • Endoscopic bilateral NP score consistent with severe CRSwNP assessed by the investigator.
  • Symptoms of Chronic rhinosinusitis (CRS)
  • Presence of symptoms of CRS for at least 12 weeks prior to Visit 1 such as rhinorrhea and/or reduction or loss of smell and
  • Moderate to severe nasal congestion/blockade/obstruction at Visit 1 based on clinical assessment by the investigator.
  • Participants must have an elevated SNOT-22 score at screening.
  • Participants must be on daily treatment with intranasal corticosteroids (INCS) (including intranasal liquid steroid wash/douching) for at least the 8 weeks prior to screening.

Exclusion criteria

  • As a result of medical interview, physical examination, or screening investigation the physician responsible considers the participant unfit for the study.
  • Have the following conditions:- Cystic fibrosis, Antrochoanal polyps, Nasal cavity tumor (malignant or benign), Fungal rhinosinusitis, Rhinitis medicamentosa, Hyper-eosinophilic syndrome (HES) Eosinophilic granulomatosis with polyangiitis (EGPA) or Churg-Strauss Syndrome or eosinophilic esophagitis, Helminth parasitic infection in the past 6 months unless treated and have responded to therapy.
  • Female who are pregnant
  • Known substance or alcohol abuse
  • Current smokers (including e-cigarettes) or ex-smokers of 6 months or less
  • Other significant medical conditions (eg immunogenicity, Human immunodeficiency virus [HIV], viral hepatitis, tuberculosis [TB], cardiac and liver disease) that could impact participants' safety or study outcomes.
  • Where nasal surgery is contraindicated
  • Nasal surgery in the past 6 months
  • Asthma exacerbation in the past 4 weeks.

Treatment and study plan

GSK5784283

Drug

GSK5784283 will be administered.

Placebo

Drug

Placebo will be administered.

Standard of care

Drug

Standard of Care will be administered.

Primary outcomes

  1. Change from Baseline in total endoscopic nasal polyps (NP) score at Week 52

    Time frame: Baseline and Week 52

    The NP score evaluated by endoscopy ranges from 0 to 4 in each nostril, with higher score indicating worse status. The total endoscopic NP score is the sum of the right and left nostril scores and ranges from 0 to 8, higher scores indicate worse status.

  2. Change from Baseline in mean nasal obstruction score using Verbal Response Scale (VRS) from Week 51 through to Week 52

    Time frame: Baseline, Weeks 51 to 52 (time - average)

    Participants will be asked to indicate the severity of nasal obstruction at their worst over the last 24 hours using a 4-point VRS ranging from 0 to 3 with higher scores indicating worse status. The average of daily scores will be calculated, and data will be presented for Weeks 51-52.

Secondary outcomes

  1. Change from Baseline in mean symptom score for loss of smell using VRS from Week 51 through to Week 52

    Time frame: Baseline, Weeks 51 to 52 (time - average)

    Participants will be asked to indicate the severity of loss of smell at their worst over the last 24 hours using a 4-point VRS ranging from 0 to 3 with higher scores indicating worse status. The average of daily scores will be calculated, and data will be presented for Weeks 51-52.

  2. Change from Baseline in the mean CRSwNP composite symptom score (average of symptom VRS scores for nasal obstruction, rhinorrhea [runny nose], loss of smell, and mucus in throat) from Week 51 through to Week 52

    Time frame: Baseline, Weeks 51 to 52 (time - average)

    The CRSwNP composite symptom score is used to evaluate the overall severity of symptoms in CRSwNP. The CRSwNP composite symptom score ranges from 0 (No symptoms) to 3 (Severe symptoms), higher score indicates worse overall symptom severity. The average of daily scores will be calculated, and data will be presented for Weeks 51-52.

  3. Change from Baseline in Lund Mackay Computed tomography (LMK CT) score at Week 52

    Time frame: Baseline and Week 52

    The Lund-Mackay CT score is a standardized radiological scoring system used to assess the severity of chronic rhinosinusitis, including CRSwNP. The LMK CT score ranges from 0 to 24 with higher scores indicating more severe sinus disease.

  4. Change from Baseline in Sino-Nasal Outcome Test (SNOT-22) total score at Week 52

    Time frame: Baseline and Week 52

    SNOT-22 is a 22-item measure of disease specific quality of life (QoL). SNOT-22 items will be measured using a 6-point rating scale ranging from 0 to 5, higher score indicates worse QoL. The SNOT-22 total score ranges from 0 to 110 with higher scores indicating greater disease impact.

  5. Time to first Nasal surgery decision or disease-modulating medication (DMM) or use of Systemic corticosteroid (SCS) for CRSwNP

    Time frame: Up to Week 52

    Time to first Nasal surgery decision (actual or entry on waiting list) or DMM or use of SCS for CRSwNP (For pooled analysis across studies 300744 and 300745) will be assessed.

  6. Time to first Nasal surgery decision or DMM

    Time frame: Up to Week 52

    Time to first Nasal surgery decision (actual or entry on waiting list) or DMM (For pooled analysis across studies 300744 and 300745) will be assessed.

  7. Time to first use of SCS for CRSwNP

    Time frame: Up to Week 52

    Time to first use of SCS for CRSwNP (For pooled analysis across studies 300744 and 300745) will be assessed.

  8. Change from Baseline in Asthma control questionnaire (5-item version) (ACQ-5) score at Week 52

    Time frame: Baseline and Week 52

    The ACQ-5 is a five-item questionnaire designed to be self-completed by the participants to assess the most common asthma symptoms. The scores range from 0 to 6. Higher scores indicated more impairment/limitations. Change from Baseline in ACQ-5 score (For pooled analysis across studies 300744 and 300745) will be assessed.

Study contacts

Contact information is provided by the study sponsor or research team.

EU GSK Clinical Trials Call Center

CONTACT

[email protected]

+44 (0) 20 89904466

US GSK Clinical Trials Call Center

CONTACT

[email protected]

877-379-3718

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Randomized, Double-blind, Parallel Group Phase 3 Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (PERSIST CRSwNP-1)

Acronym: PERSISTCRSwNP1

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Aug 24, 2026
Registry last updated
Aug 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.